放疗联合免疫卡控点阻断治疗的研究进展  

Research advances in radiotherapy combined with immune checkpoint blockade

作　　者：宋星[1] 裴红蕾[1] 

机构地区：[1]苏州大学附属第三医院放疗科,常州213003

出　　处：《中华放射肿瘤学杂志》2017年第3期348-351,共4页Chinese Journal of Radiation Oncology

基　　金：国家科技支撑计划（2015BA112812）;国家自然科学基金（31570877,31570908,81171653）;国家自然科学基金海外及港澳学者合作研究基金（31428005）;江苏省条件建设与民生科技专项资金项目（BL2014034）;江苏省卫生厅医学科研招标立项课题（H201350）

摘　　要：阻断免疫卡控点可以增强肿瘤抗原特异性T细胞反应,但是仅有小部分肿瘤患者对免疫卡控点阻断治疗敏感.研究表明放疗联合免疫卡控点阻断能促进放疗的抗原提呈作用,进一步增强肿瘤抗原特异性T细胞反应,且放疗联合免疫卡控点阻断比单一放疗或单一免疫卡控点阻断有更好的疗效.最新研究表明黑色素瘤患者放疗联合双重免疫卡控点阻断较放疗与CTLA-4阻断联合有更好的疗效.由此可见,放疗联合免疫卡控点阻断治疗将成为肿瘤治疗领域的新策略,本文即是对该方法的最新研究进展做一简述.Immune checkpoint blockade can promote the tumor-specific cytotoxic T-lymphocyte （ CTL） response. However, only a small proportion of patients have good response to immune checkpoint blockade. It has been reported that radiotherapy combined with immune checkpoint blockade can promote antigen presentation, which further enhances the tumor-specific CTL response;moreover, the combined therapy achieves better treatment outcomes than radiotherapy alone or immune checkpoint blockade alone. The latest study has shown that radiotherapy combined with dual immune checkpoint blockade has better efficacy than radiotherapy combined with CTLA-4 blockade in patients with melanoma. Therefore, radiotherapy combined with immune checkpoint blockade will become a new approach for treating tumor. This paper reviews the research advances in the combined therapy.

关 键 词：放射疗法 免疫卡控点 T淋巴细胞 

分 类 号：R730.55[医药卫生—肿瘤]